Table 2 Characteristic of cholangiocarcinoma patients for validation cohort.

From: Predicting cisplatin response in cholangiocarcinoma patients using chromosome pattern and related gene expression

Characteristic

N (%)

Gender

 

Male

20 (60.60)

Female

13 (39.40)

Age

 

Range min-max (average)

44–79 (62.5)

Subtype primary CCA

 

Intrahepatic Bile Ducts

9 (27.27)

Extrahepatic Bile Ducts

24 (72.73)

Histology

 

Tubular

27 (81.81)

Papillary

6 (18.19)

TNM Stage

 

Early stage (I–II)

11 (3.03)

Late stage (III–IV)

22(30.30)

HDRA cisplatin response

 

Response

16 (48.48)

Non-response

17 (51.52)

Total

33

Back to article page